Novacyt Aktie

Novacyt EBITDA

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Novacyt (ALNOV.PA) pr. 25. aug. 2026 er -7,49 Mio. GBP. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) -10,38 Mio. GBP — en ændring på -27,85 % (højere).

EBITDA

-7,49 Mio.GBP

YoY

-27,85%

Senest opdateret:

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Novacyt er 2026 -7,49 Mio. GBP. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Novacyt var 2025 -10,38 Mio. GBP. Det falder dermed med -27,85% højere sammenlignet med året før.

Novacyt EBITDA historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

EBITDA
Date
EBITDA
1. jan. 2017
-1,00 Mio. GBP
1. jan. 2018
66.700,00 GBP
1. jan. 2019
91.000,00 GBP
1. jan. 2020
175,99 Mio. GBP
1. jan. 2021
3,05 Mio. GBP
1. jan. 2022
-11,99 Mio. GBP
1. jan. 2023
-10,38 Mio. GBP
1. jan. 2024
-7,49 Mio. GBP
Novacyt EBITDA historik
ÅREBITDAYoY
-7,49 Mio.GBP-27,85%
-10,38 Mio.GBP-13,42%
-11,99 Mio.GBP-492,96%
3,05 Mio.GBP-98,27%
175,99 Mio.GBP+193.300,00%
91.000,00GBP+36,43%
66.700,00GBP-106,66%
-1,00 Mio.GBP-62,64%
-2,68 Mio.GBP-10,81%
-3,00 Mio.GBP-16,95%
-3,62 Mio.GBP
Access this data via the Eulerpool API

Novacyt Aktieanalyse

Hvad laver Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Novacyt aktie

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Novacyt er -7,49 Mio. GBP i 2026.

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Novacyt ændrede sig fra -10,38 Mio. GBP til -7,49 Mio. GBP, hvilket repræsenterer en ændring på -27,85 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) Novacyt siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA måler driftsresultatet før virkningen af finansieringsstruktur, skattesystem og ikke-kontante afskrivninger.

EBITDA = EBIT + Af- og nedskrivninger

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s GBP er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s Novacyt historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Novacyt

Alle nøgletal — Novacyt